519 related articles for article (PubMed ID: 21742303)
1. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
[TBL] [Abstract][Full Text] [Related]
2. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
3. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
4. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
Reibaldi M; Cardascia N; Longo A; Furino C; Avitabile T; Faro S; Sanfilippo M; Russo A; Uva MG; Munno F; Cannemi V; Zagari M; Boscia F
Am J Ophthalmol; 2010 Feb; 149(2):307-315.e2. PubMed ID: 19896635
[TBL] [Abstract][Full Text] [Related]
5. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
[TBL] [Abstract][Full Text] [Related]
6. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
Smretschnig E; Hagen S; Glittenberg C; Ristl R; Krebs I; Binder S; Ansari-Shahrezaei S
Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012
[TBL] [Abstract][Full Text] [Related]
8. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Reibaldi M; Boscia F; Avitabile T; Uva MG; Russo A; Zagari M; Occhipinti F; Russo V; Reibaldi A; Longo A
Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
[TBL] [Abstract][Full Text] [Related]
10. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Leys E; Tuttle S; Rasquin F; Neu F; Postelmans L
J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
[TBL] [Abstract][Full Text] [Related]
12. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
Arevalo JF; Espinoza JV
Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
[TBL] [Abstract][Full Text] [Related]
13. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
Sheptulin V; Purtskhvanidze K; Roider J
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
[TBL] [Abstract][Full Text] [Related]
14. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
Lim SH; Chang W; Sagong M
Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
[TBL] [Abstract][Full Text] [Related]
16. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
[TBL] [Abstract][Full Text] [Related]
17. Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab.
Byon IS; Kwon HJ; Kim SI; Shin MK; Park SW; Lee JE
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):534-41. PubMed ID: 25423633
[TBL] [Abstract][Full Text] [Related]
18. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
Goto S; Gomi F; Ueno C; Nishida K
Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
[TBL] [Abstract][Full Text] [Related]
19. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
Kim YK; Ryoo NK; Woo SJ; Park KH
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
[TBL] [Abstract][Full Text] [Related]
20. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
